NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Innovent Biologics (Suzhou) Co. Ltd.
China Medical University Hospital
Coherus Oncology, Inc.
Centre Oscar Lambret
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Federation Francophone de Cancerologie Digestive
Akeso
First Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University